- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03767153
Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring
Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Port Orange, Florida, United States, 32127
- Leavitt Medical Associates of Florida d/b/a Ameriderm Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, male or female subjects 22 years of age or over who are seeking treatment and reduction of their facial acne scarring.
- Able to read, understand and voluntarily provide written Informed Consent.
- Able and willing to comply with the treatment/follow-up schedule and requirements.
- Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.
Exclusion Criteria:
- Implantable defibrillators, cardiac pacemakers, and other metal implants
- Subjects with any implantable metal device in the treatment area
- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
- Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.
- Current or history of any kind of cancer, or pre-malignant moles.
- Severe concurrent conditions, such as cardiac disorders.
- Pregnancy or intending to become pregnant during the study and nursing.
- Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
- History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to enrollment, or according to Investigator's discretion .
- Poorly controlled endocrine disorders, such as diabetes.
- Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
- History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
- History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).
- Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.
- Use of isotretinoin (Accutane®) or other retinoids within six months prior to treatment or as per physician's discretion.
- Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one week before and after each treatment session.
- Any surgical procedure in the treatment area within the last six months or before complete healing.
- Treating over tattoo or permanent makeup.
- Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
- As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 80 pin applicator
|
The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits. |
Active Comparator: 160 pin applicator
|
The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Acne Scar Improvement Assessed by the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks.
Time Frame: 12 Weeks Post-Final Treatment
|
Evaluate the efficacy of overall facial acne scar improvement assessed live by the Investigator and a subject assessment of facial appearance including the Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale is a seven-grade subjective test. Three independent evaluators evaluated before and after photographs and graded them for change. Possible responses were (3) Very Much Improved, (2) Much Improved, (1) Improved, (0) No Change, (-1) Worse, (-2) Much Worse, and (-3) Very Much Worse. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range -3 to 3). |
12 Weeks Post-Final Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Satisfaction
Time Frame: 6 Weeks and 12 Weeks Post- Final Treatment
|
Subjects' assessment of satisfaction with the treatment using a 5 point Subject Satisfaction Scale at 6 Weeks and 12 weeks post-treatment. The Subject Satisfaction Scale is a five-grade subjective test. Participant were asked their satisfaction level post treatment. Possible responses were (4) Very Satisfied, (3) Satisfied, (2) Having No Opinion, (1) Unsatisfied, and (0) Very Unsatisfied. |
6 Weeks and 12 Weeks Post- Final Treatment
|
Subject Scale - Visual Analog Scale for Pain
Time Frame: 12 Weeks Post-Final Treatment
|
Subject's assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS). The Visual Analog Scale is a scale from 0 cm (no pain) and 10 cm (pain as bad as it can be). Possible responses were of 0 to 0.4 cm can be considered (no pain); 0.5 to 4.4 cm (mild pain), 4.5 to 7.4 cm (moderate pain), and 7.5 to 10 cm (severe pain). |
12 Weeks Post-Final Treatment
|
Number of Participants With Treatment-Related Adverse Events [Safety]
Time Frame: Up to 12 Weeks Post-Final Treatment
|
Subjects experiencing a treatment-related adverse event (AE) by 12 weeks post-treatment.
|
Up to 12 Weeks Post-Final Treatment
|
Subject Scale - 5 Point Scale for Treatment Tolerability
Time Frame: 12 Weeks Post-Final Treatment
|
Subject's assessment of treatment tolerability as measured by a 5 point scale. Participant were asked their tolerability level post treatment. Possible scores were; (4) Very Tolerable, (3) Tolerable, (2) Having No Opinion, (1) Intolerable, and (0) Very Intolerable. |
12 Weeks Post-Final Treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VI1018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Scars
-
Ulthera, IncCompleted
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Northwestern UniversityActive, not recruiting
-
Massachusetts General HospitalUnknown
-
Goldman, Butterwick, Fitzpatrick and GroffCynosure, LLCNot yet recruitingAcne Scars
-
Cynosure, Inc.Completed
-
Massachusetts General HospitalAmerican Society for Dermatologic SurgeryCompleted
-
Dongtan Sacred Heart HospitalUnknownAcne ScarsKorea, Republic of
-
Skincare Physicians of Chestnut HillCandela CorporationCompletedAcne Scars | AcneUnited States
-
Cynosure, Inc.Active, not recruitingAcne ScarsUnited States
Clinical Trials on Venus Viva
-
Venus ConceptCompleted
-
Venus ConceptCompletedWrinkle | RhytidesUnited States
-
Venus ConceptCompletedAcne Scars - Mixed Atrophic and Hypertrophic | WrinkleUnited States
-
Venus ConceptCompletedWrinkle | RhytidesUnited States
-
Venus ConceptCompletedAcne Scars - Mixed Atrophic and HypertrophicUnited States
-
Chulalongkorn UniversityVenus ConceptUnknownSkin Tightening and RejuvenationThailand
-
Venus ConceptCompletedAcne ScarsUnited States
-
Venus ConceptCompletedVulvovaginal AtrophyItaly, Spain
-
Venus MedTech (HangZhou) Inc.UnknownAortic Valve Stenosis | Aortic Valve CalcificationChina
-
University of AlbertaMitacs; Canadian Foundation for Dietetic Research (CFDR); Revive Wellness Inc.CompletedPhysical Activity | Stress | Health Behavior | NutritionCanada